Roberts Glore & Co. Inc. IL Purchases New Position in Zimmer Biomet Holdings, Inc. $ZBH

Roberts Glore & Co. Inc. IL acquired a new position in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund acquired 6,742 shares of the medical equipment provider’s stock, valued at approximately $580,000.

Other hedge funds also recently modified their holdings of the company. DV Equities LLC bought a new stake in shares of Zimmer Biomet in the 4th quarter worth $25,000. Tacita Capital Inc bought a new stake in Zimmer Biomet in the 2nd quarter worth about $26,000. Ancora Advisors LLC purchased a new stake in Zimmer Biomet in the 2nd quarter valued at about $29,000. Monetary Solutions Ltd bought a new position in shares of Zimmer Biomet during the 4th quarter worth approximately $30,000. Finally, Gen Wealth Partners Inc purchased a new position in shares of Zimmer Biomet in the 4th quarter worth approximately $31,000. Hedge funds and other institutional investors own 88.89% of the company’s stock.

Zimmer Biomet Stock Performance

Zimmer Biomet stock opened at $100.25 on Wednesday. Zimmer Biomet Holdings, Inc. has a fifty-two week low of $79.12 and a fifty-two week high of $108.29. The company has a debt-to-equity ratio of 0.50, a quick ratio of 0.94 and a current ratio of 1.69. The stock has a market cap of $19.12 billion, a P/E ratio of 24.39, a price-to-earnings-growth ratio of 2.75 and a beta of 0.45. The firm’s fifty day moving average price is $93.11 and its 200-day moving average price is $91.22.

Zimmer Biomet (NYSE:ZBH) last released its earnings results on Wednesday, August 5th. The medical equipment provider reported $2.07 EPS for the quarter, beating analysts’ consensus estimates of $2.01 by $0.06. Zimmer Biomet had a return on equity of 13.12% and a net margin of 9.48%.The business had revenue of $2.18 billion for the quarter, compared to analysts’ expectations of $2.13 billion. During the same quarter in the prior year, the firm earned $2.07 earnings per share. The firm’s revenue was up 4.8% on a year-over-year basis. Zimmer Biomet has set its FY 2026 guidance at 8.470-8.590 EPS. On average, equities research analysts expect that Zimmer Biomet Holdings, Inc. will post 8.54 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

ZBH has been the topic of a number of recent analyst reports. Citigroup lowered their target price on Zimmer Biomet from $95.00 to $93.00 and set a “neutral” rating on the stock in a research note on Thursday, May 28th. Sanford C. Bernstein increased their target price on shares of Zimmer Biomet from $91.00 to $93.00 and gave the stock a “market perform” rating in a research report on Thursday, August 6th. Needham & Company LLC reaffirmed a “hold” rating on shares of Zimmer Biomet in a report on Wednesday, August 5th. Canaccord Genuity Group boosted their target price on shares of Zimmer Biomet from $83.00 to $100.00 and gave the company a “hold” rating in a report on Monday, August 10th. Finally, UBS Group reaffirmed a “buy” rating and issued a $120.00 price target on shares of Zimmer Biomet in a report on Thursday, August 6th. One investment analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, thirteen have given a Hold rating and three have assigned a Sell rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average target price of $104.42.

Insider Buying and Selling at Zimmer Biomet

In other Zimmer Biomet news, insider Sang Yi sold 5,000 shares of the company’s stock in a transaction that occurred on Friday, May 29th. The stock was sold at an average price of $82.64, for a total value of $413,200.00. Following the completion of the sale, the insider owned 27,251 shares of the company’s stock, valued at $2,252,022.64. This represents a 15.50% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Corporate insiders own 1.28% of the company’s stock.

Zimmer Biomet Profile

Zimmer Biomet (NYSE: ZBH) is a global medical device company focused on musculoskeletal healthcare. Headquartered in Warsaw, Indiana, the company designs, manufactures and markets a broad portfolio of products used to treat joint disorders, bone disorders and related conditions. Its customer base includes orthopaedic and dental surgeons, hospitals, ambulatory surgery centers and other healthcare providers that rely on implants, instruments and related services for reconstructive and restorative procedures.

The company’s product offerings span joint replacement systems for hips, knees and shoulders; trauma and extremities implants; spine and thoracic solutions; dental and craniomaxillofacial implants and prosthetics; and sports medicine devices.